The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Kortylewski, Marcin ^a   Pal, Sumanta K ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Cancer recurrence; IL 6; Myeloid cells; NF B; Radiotherapy; STAT3; TLR9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BONE MARROW CELL; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; GENE TARGETING; HUMAN; IONIZING RADIATION; NONHUMAN; RADIATION RESPONSE; RADIATION SAFETY; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84899059250     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27894     Document Type: Article

References (10)

1. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014.
2. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723-37; PMID:21997792; http://dx.doi. org/10.1038/nri3073.
3. Roses RE, Xu M, Koski GK, Czerniecki BJ. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 2008; 27:200-7; PMID:18176601; http://dx.doi.org/10.1038/sj.onc.1210909.
4. Kozin SV, Duda DG, Munn LL, Jain RK. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J Natl Cancer Inst 2012; 104:899-905; PMID:22572994; http://dx.doi.org/10.1093/jnci/djs239.
5. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx.doi.org/10.1038/nrc2734.
6. Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain DM, Kowolik CM, Chu P, Swiderski P, Diamond DJ, et al. TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res 2013; 73:7211-21; PMID:24154870; http://dx.doi.org/10.1158/0008-5472.CAN-13-1314.
7. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104-7; PMID:20203610; http://dx.doi.org/10.1038/nature08780.
8. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009; 27:925-32; PMID:19749770; http://dx.doi.org/10.1038/nbt.1564.
9. Zhang Q, Hossain DM, Nechaev S, Kozlowska A, Zhang W, Liu Y, Kowolik CM, Swiderski P, Rossi JJ, Forman S, et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood 2013; 121:1304-15; PMID:23287859; http://dx.doi.org/10.1182/blood-2012-07-442590.
10. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010; 28:4324-32; PMID:20697067; http://dx.doi.org/10.1200/JCO.2010.28.9793.